S-1与顺铂联合治疗晚期或复发性胃癌患者的长期疗效

Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer.

作者信息

Sakaguchi Yoshihisa, Kabashima Akira, Okita Keishi, Ojima Yasutomo, Yamamura Shinji, Nishizaki Takashi, Tashiro Hideya, Matsusaka Toshimitsu

机构信息

Department of Surgery, Matsuyama Red Cross Hospital, 1 Bunkyoumachi, Matsuyama, Ehime 790-8524, Japan.

出版信息

Gastric Cancer. 2005;8(2):111-6. doi: 10.1007/s10120-004-0313-4.

DOI:10.1007/s10120-004-0313-4

PMID:15864718

Abstract

BACKGROUND

Although combination therapy of S-1 and cisplatin (CDDP) has excellent efficacy against gastric cancer, the effect of the treatment on survival has been unclear. The aim of this study was to evaluate the long-term outcome of this combination therapy.

METHODS

Sixty-three patients with advanced or recurrent gastric cancer were treated with S-1, with or without CDDP, as first-line chemotherapy, and the clinical results were compared retrospectively. S-1 was administered orally at a standard dose of 80 mg/m(2). In the treatment of the S-1 group, S-1 was given for 28 consecutive days, followed by a 14-day rest. In the treatment of the S-1/CDDP group, S-1 was given for 21 consecutive days, followed by a 14-day rest, and CDDP, at 60 mg/m(2), was infused on day 8.

RESULTS

The incidence of adverse reactions of more than grade 3 was 22.5% in the S-1 group and 43.5% in the S-1/CDDP group, and the treatment compliance was better in the S-1 group. The overall response rate was 25.9% in the S-1 group, and 36.8% in the S-1/CDDP group. The combination of S-1 with CDDP had better effects on the primary lesion and on differentiated-type carcinoma than S-1 alone. However, there was no difference in survival between the two patient groups. The median survival time after the initiation of treatment in the S-1 group was 322 days, and that in the S-1/CDDP group was 319 days.

CONCLUSIONS

Our results suggest that the combination of CDDP with S-1 does not improve the long-term outcome of S-1 therapy.

摘要

背景

尽管S-1与顺铂（CDDP）联合治疗对胃癌具有良好疗效，但该治疗对生存期的影响尚不清楚。本研究旨在评估这种联合治疗的长期疗效。

方法

63例晚期或复发性胃癌患者接受S-1治疗，无论是否联合CDDP，作为一线化疗，并对临床结果进行回顾性比较。S-1按标准剂量80mg/m²口服给药。在S-1组治疗中，S-1连续给药28天，随后休息14天。在S-1/CDDP组治疗中，S-1连续给药21天，随后休息14天，CDDP 60mg/m²于第8天静脉滴注。

结果

S-1组3级以上不良反应发生率为22.5%，S-1/CDDP组为43.5%，S-1组治疗依从性更好。S-1组总缓解率为25.9%，S-1/CDDP组为36.8%。S-1与CDDP联合对原发灶和分化型癌的疗效优于单独使用S-1。然而，两组患者的生存期无差异。S-1组治疗开始后的中位生存期为322天，S-1/CDDP组为319天。